Pluristem (Israel) Top Management
| PSTI Stock | ILS 1,922 7.00 0.36% |
Pluristem employs about 153 people. The company is managed by 17 executives with a total tenure of roughly 138 years, averaging almost 8.0 years of service per executive, having 9.0 employees per reported executive. Analysis of Pluristem's management performance can provide insight into the company performance.
| Zalman Aberman Chairman Chairman of the Board, CEO |
| Yaky Yanay President President, CFO, COO, Secretary and Director |
Pluristem |
Pluristem Management Team Effectiveness
The company has return on total asset (ROA) of (0.3735) % which means that it has lost $0.3735 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8655) %, meaning that it generated substantial loss on money invested by shareholders. Pluristem's management efficiency ratios could be used to measure how well Pluristem manages its routine affairs as well as how well it operates its assets and liabilities.Pluristem Workforce Comparison
Pluristem is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is at this time estimated at about 25,557. Pluristem maintains roughly 153 in number of employees contributing less than 1% to stocks in Biotechnology industry.
Pluristem Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Pluristem Price Series Summation is a cross summation of Pluristem price series and its benchmark/peer.
Pluristem Notable Stakeholders
A Pluristem stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pluristem often face trade-offs trying to please all of them. Pluristem's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pluristem's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Zalman Aberman | Chairman of the Board, CEO | Profile | |
| Yaky Yanay | President, CFO, COO, Secretary and Director | Profile | |
| Karine Kleinhaus | Divisional Vice President North-America | Profile | |
| Chen FrancoYehuda | CFO, Treasurer, Secretary | Profile | |
| Erez Egozi | CFO | Profile | |
| Mark Germain | Director | Profile | |
| Nachum Rosman | Independent Director | Profile | |
| Israel BenYoram | Independent Director | Profile | |
| Doron Shorrer | Lead Independent Director | Profile | |
| Issac Braun | Director | Profile | |
| Hava Meretzki | Director | Profile | |
| Moria Kwiat | Director | Profile | |
| Lior Raviv | Chief Officer | Profile | |
| Efrat LivneHadass | VP HR | Profile | |
| Yaacov Yanay | CEO Pres | Profile | |
| Nimrod Zvi | Chief Officer | Profile | |
| Nitsan MD | Chief Officer | Profile |
About Pluristem Management Performance
The success or failure of an entity such as Pluristem often depends on how effective the management is. Pluristem management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pluristem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pluristem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. PLURISTEM THERAPEU operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 172 people.
The data published in Pluristem's official financial statements usually reflect Pluristem's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pluristem. For example, before you start analyzing numbers published by Pluristem accountants, it's critical to develop an understanding of what Pluristem's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Pluristem's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pluristem's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pluristem's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pluristem. Please utilize our Beneish M Score to check the likelihood of Pluristem's management manipulating its earnings.
Pluristem Workforce Analysis
Traditionally, organizations such as Pluristem use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pluristem within its industry.Pluristem Manpower Efficiency
Return on Pluristem Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 325.9K | |
| Net Loss Per Executive | 2.9M | |
| Working Capital Per Employee | 222.2K | |
| Working Capital Per Executive | 2M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pluristem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Pluristem Stock analysis
When running Pluristem's price analysis, check to measure Pluristem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluristem is operating at the current time. Most of Pluristem's value examination focuses on studying past and present price action to predict the probability of Pluristem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluristem's price. Additionally, you may evaluate how the addition of Pluristem to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |